Latest News & Features
Genetics
The World Intellectual Property Office has launched a course on IP and genetic resources in the life sciences. 6 May 2021
Big Pharma
Sanofi-Aventis has been awarded $17.2 million in attorney fees, legal expenses and interest in a district court ruling on a failed suit levied by Amphastar Pharmaceuticals. 6 May 2021
article
Patent litigation is increasingly a multi-jurisdiction, cross-border affair that requires strategic consideration. When protecting patents on a global sphere you have to understand the balance between risks and benefits for each jurisdiction. Patent laws vary from country to country, and so must your strategy. 6 May 2021
Medtech
US medtech company Conformis has filed a lawsuit against J&J Medical Devices-owned DePuy Synthes, alleging that it infringed on its custom implant and surgery software patents. 4 May 2021
Americas
Pharmaceutical company Novartis has abandoned its attempt to halt US imports of Regeneron’s Eylea pre-filled syringes amid concerns that such a ban could hinder public access to essential treatments. 4 May 2021
Medtech
The US Court of Appeals for the Federal Circuit has affirmed a US International Trade Commission (ITC) decision that ruled Bio-Rad Laboratories had infringed three 10x Genomics patents. 4 May 2021
Americas
GlaxoSmithKline has submitted an amicus brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.” 29 April 2021
Americas
Amarin delayed the market entry of generic versions of the cardiovascular drug Vascepa by using supply agreements to halt competitors from accessing the drug’s active pharmaceutical ingredient, according to a new antitrust lawsuit. 29 April 2021
Generics
Mylan can deduct legal fees from defending itself against patent infringement suits as business expenses, according to the US Tax Court. 29 April 2021
article
As patent protections expire, drug repositioning has become a matter of intense interest. Aris Persidis founded Biovista in 2005 and has focused on using artificial intelligence to match drugs against any and all mechanisms, pathways, diseases and clinical outcomes. 29 April 2021